RSV genetic vaccine

The **RSV genetic vaccine** is a discontinued preclinical-stage vaccine candidate developed by **Precigen** (formerly Intrexon) in collaboration with **Harvest Fund Management**. The program utilized a genetic immunization approach, likely involving DNA or a viral vector (such as Precigen's gorilla adenovirus platform), to deliver sequences encoding **respiratory syncytial virus (RSV)** antigens. The goal was to induce both humoral and cellular immune responses to prevent RSV infection. The program was mentioned in early research publications but was subsequently removed from the active corporate pipeline, indicating it is no longer being pursued for clinical development.